A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

NCT03913949 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma

Interventions

DRUG: APG-2575

Sponsor

Ascentage Pharma Group Inc.

Collaborators

[object Object]